NUMA1 and breast cancer: The FDA has now approved six urinary diagnostic assays for BC: qualitative bladder tumor antigen (BTA) (BTA stat), quantitative BTA (BTA TRAK), quantitative nuclear matrix protein 22 (NMP22) (Alere NMP22), qualitative NMP22 (BladderCheck), fluorescent immunohistochemistry (ImmunoCyt), and fluorescence in situ hybridization (FISH) (UroVysion) for clinical use [113].